Eisai Inc.: Eisai Announces Exclusive In-License of All U.S. Promotional Rights for Fragmin(R), an Injectable Anti-Clotting Agent
28th Sep 2005, 09:25 GMT
TEANECK, NJ (MARKET WIRE) Eisai Inc. (Headquarters: Teaneck, Chairman and CEO: Hajime Shimizu), a U.S. pharmaceutical subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito), today announced an in-license agreement with Pfizer Inc for exclusive U.S. rights to promote Fragmin(R) (dalteparin sodium injection), an anti-coagulant. Eisai also will assume responsibility for post-marketing studies and product
Latest news from Market Wire - Pharmaceuticals and Biotech:
- Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
- IBEX TECHNOLOGIES INC.: IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis
- Daiichi Sankyo, Inc.: First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Daiichi Sankyo, Inc.: WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
- Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting
- Crucell N.V.: Crucell Announces Third Quarter 2006 Results
- Acambis PLC: Acambis PLC announces Update on US MVA procurement
- SkyePharma PLC: SkyePharma PLC announces Board Appointment
- Base Technologies, Inc.: Base Technologies Award of Air Force Surgeon General Contract Continues Rapid Growth Trend
- Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech